Skip to main content
. Author manuscript; available in PMC: 2021 Jun 28.
Published in final edited form as: Cancer Immunol Res. 2019 Jan 25;7(3):401–413. doi: 10.1158/2326-6066.CIR-18-0546

Figure 2. In vivo effect of NIR-PIT and PD-1 mAb in mice bearing a unilateral MC38-luc tumors.

Figure 2.

(A) NIR-PIT regimen. Bioluminescence and fluorescence images were obtained at each time point as indicated. (B) Light exposure. NIR light was administered to the unilateral right-sided tumor. (C) In vivo IR700 fluorescence real-time imaging of tumor-bearing mice in response to NIR-PIT (n=10). (D) In vivo BLI of tumor bearing mice in response to NIR-PIT. Mice in the PD-1 mAb group also received CD44-IR700 but were not treated with NIR. (E) Quantification of luciferase activity in four treatment groups (n ≧ 10, **p < 0.01 vs. control, Tukey’s t test with ANOVA; #p < 0.05 vs. PD-1 mAb and NIR-PIT groups, Tukey’s t test with ANOVA). (F) Resected tumors (day 10) were stained with H&E and assessed for necrosis and leukocyte infiltration. White scale bars = 100 μm. Black scale bars = 20 μm. (G) Tumor growth curves (n ≧ 10, **p < 0.01 vs control, Tukey’s t test with ANOVA; ##p < 0.01 vs PD-1 mAb and NIR-PIT groups, Tukey’s t test with ANOVA). (H) Kaplan-Meier survival analysis following NIR-PIT treatment with and without PD-1 mAb (**p < 0.01 vs. control, Log rank test; ##p < 0.01 vs. PD-1 mAb and NIR-PIT groups, Log rank test).